Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Acosta

Showing results (271-280 of 338) with videos related to

Pageof 34
Sort By:
The Journal of Infectious Diseases|June 27, 2013
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248Adriana Andrade, Susan L Rosenkranz, Anthony R Cillo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 28, 2014
Raltegravir pharmacokinetics in neonates following maternal dosingDiana F Clarke, Edward P Acosta, Matthew L Rizk, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 16, 2004
Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individualsEdward P Acosta, Hulin Wu, Scott M Hammer, et al.
European Journal of Pediatrics|October 24, 2000
The International Collaborative Study of Maternal Phenylketonuria: status report 1998R Koch, E Friedman, C Azen, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 9, 2020
Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110)Diana F Clarke, Edward P Acosta, Mae Cababasay, et al.
Journal of the Pediatric Infectious Diseases Society|April 6, 2019
Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 StudyRolando M Viani, Theodore Ruel, Carmelita Alvero, et al.
The Journal of Infectious Diseases|July 5, 2005
Nutritional status and serum cytokine profiles in children, adolescents, and young adults with Schistosoma japonicum-associated hepatic fibrosis, in Leyte, PhilippinesHannah M Coutinho, Stephen T McGarvey, Luz P Acosta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 23, 2013
Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 yearsSharon Nachman, Nan Zheng, Edward P Acosta, et al.
Antimicrobial Agents and Chemotherapy|January 16, 2019
Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202Cindy J Bednasz, Charles S Venuto, Qing Ma, et al.
The Journal of Infectious Diseases|February 19, 2008
Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus diseaseDavid W Kimberlin, Edward P Acosta, Pablo J Sánchez, et al.
Pageof 34

Showing results (271-280 of 338) with videos related to

Sort By:
Pageof 34
The Journal of Infectious Diseases|June 27, 2013
Three distinct phases of HIV-1 RNA decay in treatment-naive patients receiving raltegravir-based antiretroviral therapy: ACTG A5248Adriana Andrade, Susan L Rosenkranz, Anthony R Cillo, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|August 28, 2014
Raltegravir pharmacokinetics in neonates following maternal dosingDiana F Clarke, Edward P Acosta, Matthew L Rizk, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 16, 2004
Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individualsEdward P Acosta, Hulin Wu, Scott M Hammer, et al.
European Journal of Pediatrics|October 24, 2000
The International Collaborative Study of Maternal Phenylketonuria: status report 1998R Koch, E Friedman, C Azen, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|January 9, 2020
Raltegravir (RAL) in Neonates: Dosing, Pharmacokinetics (PK), and Safety in HIV-1-Exposed Neonates at Risk of Infection (IMPAACT P1110)Diana F Clarke, Edward P Acosta, Mae Cababasay, et al.
Journal of the Pediatric Infectious Diseases Society|April 6, 2019
Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 StudyRolando M Viani, Theodore Ruel, Carmelita Alvero, et al.
The Journal of Infectious Diseases|July 5, 2005
Nutritional status and serum cytokine profiles in children, adolescents, and young adults with Schistosoma japonicum-associated hepatic fibrosis, in Leyte, PhilippinesHannah M Coutinho, Stephen T McGarvey, Luz P Acosta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 23, 2013
Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 yearsSharon Nachman, Nan Zheng, Edward P Acosta, et al.
Antimicrobial Agents and Chemotherapy|January 16, 2019
Race/Ethnicity and Protease Inhibitor Use Influence Plasma Tenofovir Exposure in Adults Living with HIV-1 in AIDS Clinical Trials Group Study A5202Cindy J Bednasz, Charles S Venuto, Qing Ma, et al.
The Journal of Infectious Diseases|February 19, 2008
Pharmacokinetic and pharmacodynamic assessment of oral valganciclovir in the treatment of symptomatic congenital cytomegalovirus diseaseDavid W Kimberlin, Edward P Acosta, Pablo J Sánchez, et al.
Pageof 34